AIMS: The aim of this systematic review was to assess the effects of Spirulina supplementation on metabolic syndrome components, its liver manifestation and related inflammatory markers.METHODS: We searched PubMed and Scopus (up to August 2017) to identify relevant studies. English randomized controlled trials (RCTs) investigating the effects of Spirulina supplementation on factors associated with metabolic syndrome in human models, were included in the review.RESULTS: Among 720 articles related to Spirulina in the primary search, 22 of them were eligible human RCTs and finally 18 of them were included in the review. The systematic review revealed that oral dosage range of 1-19gr/day for 0.5-6 months of Spirulina supplementation have positive effects on metabolic syndrome components.CONCLUSION: Spirulina can be possibly administered as a safe and efficient supplementation in the case of metabolic syndrome components, although determining the optimal dosage and period of supplementation still needs further investigations.
Animals Biomarkers